Research overview
IGF-1 LR3: what the research shows
What is IGF-1 LR3?
IGF-1 LR3, published as Long [Arg3]-IGF-I or Long R3 IGF-I, is a recombinant analog of human insulin-like growth factor 1 (IGF-1). It was described in 1992 as one of several fusion-protein analogs designed as reagents for investigating IGF-1 action [2].
It differs from native IGF-1 in two ways. First, glutamate at position 3 is replaced by arginine. Second, a 13-amino-acid extension is attached to the N terminus, made up of methionine plus the first 11 amino acids of porcine growth hormone, followed by Val-Asn [2] [3]. The native human IGF-1 chain is 70 amino acids long [1], so the full analog is 83 residues.
The key property of the analog is that it binds IGF-binding proteins (IGFBPs) very poorly. The original authors reported that its greater potency in cell systems came from this reduced IGFBP interaction rather than from stronger binding to the IGF-1 receptor itself [2] [4]. IGF-1 LR3 is a recombinant protein, not a short synthetic peptide, and PubChem does not hold a compound record for it.
| Structure | Human IGF-1 with Glu3 replaced by Arg, plus a 13-residue N-terminal extension: Met1-porcine GH(1-11)-Val-Asn |
|---|---|
| Length | 83 amino acids (13-residue extension plus the 70-residue IGF-1 chain) |
| Parent protein | Insulin-like growth factor 1, human (UniProt P05019, mature chain residues 49 to 118) |
| Origin | Recombinant, first produced in Escherichia coli as a fusion protein analog |
| Other names | Long R3 IGF-I, Long [Arg3]-IGF-I, LR3-IGF-I |
Mechanisms studied
Reduced IGF-binding protein interaction
The groundwork came from a 1992 study of Arg3 and Gly3 substitutions in IGF-I. Both analogs were more potent than IGF-I in rat L6 myoblast assays of protein and DNA synthesis, bound very poorly to bovine IGFBP-2, and bound the type 1 IGF receptor slightly less well than IGF-I. The authors concluded that reduced IGFBP binding, rather than increased receptor binding, explained the greater biological potency [4].
The companion study that introduced the N-terminal extension found that, in cell lines secreting IGFBPs into the medium, the Long Arg3 analog was among the most potent forms tested. In chicken embryo fibroblasts, which secrete no detectable IGFBPs, it was less potent than IGF-I [2]. That contrast is a direct demonstration that the analog's advantage depends on the presence of binding proteins.
Structural basis
A 2000 NMR solution structure of Long-[Arg3]-IGF-I found that the IGF-I domain kept the overall fold of native IGF-I, with the main differences at the N terminus, where the first three residues of the IGF-I domain were substantially reoriented. The authors linked this to its lower affinity for IGFBPs and also observed considerable flexibility in the N-terminal extension [3].
IGF-1 receptor signaling
IGF-1 LR3 acts through the type 1 IGF receptor (IGF-1R). In a 2001 cell study, IGFBP-3 inhibited receptor phosphorylation induced by IGF-I, IGF-II, des(1-3)IGF-I, and Long R3 IGF-I in a concentration-dependent manner. The authors attributed this to sequestration of the ligands in the extracellular space rather than any direct interaction of IGFBP-3 with the receptor [5], which clarifies that even this low-affinity analog can be bound when IGFBP-3 is abundant.
Receptor binding varies by species and cell type
In turkey satellite cells and embryonic myoblasts grown in serum-free medium, a chicken LR3 IGF-I analog was less active than chicken IGF-I and competed less effectively for receptor binding. The authors noted that changes made to avoid binding proteins can also alter receptor affinity [6].
Areas of research
Cell culture and bioprocessing
Because it remains active in the presence of cell-secreted IGFBPs [2], IGF-1 LR3 has been used as a growth-factor supplement in cell culture. In one example, a study of transient monoclonal antibody production in Chinese hamster ovary (CHO) cells reported that adding LR3-IGF extended culture duration and increased product titer, with a larger effect when combined with mild hypothermia [7].
IGF axis feedback in animal physiology
Animal studies have used IGF-1 LR3 to probe feedback within the GH and IGF system, with results that differ by species. In guinea pigs, seven days of exposure increased the relative weights of several organs but did not stimulate overall growth, and plasma IGF-I, IGF-II, and IGFBP concentrations fell [8]. In finisher pigs, four days of exposure decreased growth and food intake and suppressed plasma GH, IGFBP-3, IGF-I, and insulin, which the authors attributed to suppression of GH secretion [9]. These findings show that an IGFBP-resistant analog can trigger strong negative feedback on the axis.
Neuroscience models
A 2025 study in male 5XFAD mice, a model of amyloid pathology, reported that long-term IGF-1 LR3 exposure was associated with remodeling of amyloid plaques in the cortex and increased amyloid-beta uptake by BV-2 microglial cells in vitro, but did not preserve behavior or memory in that model [10].
Open research questions
- How IGFBP-resistant signaling differs from native IGF-1 signaling at the level of receptor activation kinetics and downstream pathways.
- Species differences in receptor affinity for long-extension analogs, which complicate cross-species comparison [6].
- The consequences of bypassing IGFBP regulation over long periods, given that IGF-1 receptor activation stimulated DNA synthesis in the original cell assays [4].
State of the human evidence
We found no published clinical trials of IGF-1 LR3 in PubMed. Its literature consists of biochemistry, cell culture, and animal physiology. A 2026 narrative review of GH-axis peptides used outside medical supervision grouped IGF-1 LR3 with other compounds that circulate without regulatory approval, described the evidence for such agents as ranging down to a complete absence of human studies, and raised biologically plausible but unproven concerns about mitogenic effects [11].
Product identity is a further concern outside controlled supply. A 2010 doping-control case report identified a His-tagged form of Long-R3-IGF-I, normally a biochemical research reagent, in a vial obtained from the black market, and noted that the effects of that form in humans had not been described [12]. IGF-1 LR3 should be regarded as a laboratory reagent only.
Regulatory status
- Not FDA approved. IGF-1 LR3 is not an approved drug. A Drugs@FDA search on October 12, 2026 found approved products only for unmodified recombinant human IGF-1 (mecasermin), which is a different molecule [13].
- Compounding. IGF-1 LR3 does not appear on FDA's list of bulk drug substances that may present significant safety risks (content current as of April 22, 2026) [14]. Absence from that list is not an authorization for any human use.
- Sport. The World Anti-Doping Agency 2026 Prohibited List names insulin-like growth factor 1 (IGF-1) and its analogues under S2.3, growth factors and growth factor modulators, within class S2, which is prohibited at all times [15].
Status checked October 12, 2026. Rejuvatide supplies IGF-1 LR3 strictly as a research reagent for in vitro and laboratory use. It is not sold for human or veterinary use.
Testing and quality
A certificate of analysis for the current lot of IGF-1 LR3 can be requested through our COA library. Because the published literature includes tagged and otherwise modified variants of this protein [12], confirm that the certificate's identity result matches the untagged 83-residue analog before comparing results with published work.
Related IGF-axis research compounds include MGF and PEG-MGF. Browse all growth-axis research peptides, or see our FAQ for ordering and shipping questions.
Storage of lyophilized material
IGF-1 LR3 ships as a lyophilized (freeze-dried) powder, which is stable at ambient temperature during transit. For long-term storage, keep sealed vials at -20°C, protected from light and moisture. Allow a vial to reach room temperature before opening to limit condensation. Handling of any prepared solutions should follow your laboratory's own validated procedures.